MRKR - Marker Therapeutics GAAP EPS of -$0.11 misses by $0.01 revenue of $0.79M misses by $1.71M

• Marker Therapeutics press release ( NASDAQ: MRKR ): Q2 GAAP EPS of -$0.11 misses by $0.01 .
• Revenue of $0.79M misses by $1.71M .
• “We are very optimistic about the ability of MT-401 to drive results for patients with measurable residual disease given the results we have seen to date in the ARTEMIS study,” said Dr. Mythili Koneru, Marker’s Chief Medical Officer. “Of note, we were very pleased to note that the second patient we treated with MRD+ disease was found to be MRD- by that patient’s week 8 follow-up. The ability to administer MT-401 without the need for lymphodepletion, coupled with our improved accelerated manufacturing process, enable us to treat patients who have MRD+ disease. We believe that the results observed to date support the notion that patients with AML would have meaningful benefit from a multi-antigen targeted T cell therapy approach.”

For further details see: